Dr. Choueiri on Avelumab Plus Axitinib in mRCC

Video

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses phase I results of axitinib (Inlyta) plus avelumab (Bavencio) for the treatment of patients with metastatic renal cell carcinoma (RCC).

Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses phase I results of axitinib (Inlyta) plus avelumab (Bavencio) for the treatment of patients with metastatic renal cell carcinoma (RCC).

Axitinib is a standard VEGF therapy for the second-line setting and demonstrates a good response rate, Choueiri explains. It also has shown promise as a frontline therapy, though it is not yet approved in that setting by the FDA. Avelumab is approved by the FDA for treatment of patients with Merkel cell carcinoma and for patients with advanced refractory urothelial carcinoma.

The combination of these 2 agents does have some associated toxicities but, overall, showed no dose-limiting tocities. An expansion phase did also show toxicities related mainly with axitinib or avelumab. Moreover, there was an approximate 60% response rate, justifying the ongoing phase III trial of axitinib plus avelumab versus sunitinib (Sutent) that is currently ongoing.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,